HeFH is an inherited disease that is characterized by very high LDL-C levels and familial patterns of increased risk of premature coronary artery disease and heart disease-related death due to these elevated LDL-C levels. The majority of these patients have inherited abnormalities in the gene for the LDL receptor. This results in a decreased ability to clear LDL-C from the blood and consequently leads to high levels of LDL-C in the blood that can accelerate the initiation and progression of atherosclerosis. [ 6] As a result of the severe elevations in LDL-C, many of these patients cannot reach treatment goals with existing therapies. A recent analysis of 1,249 heFH patients found that only 21% were able to achieve a treatment goal of <2.5 mmol/L (<97 mg/dL). [ 7] It is estimated that 1 in 500 people worldwide carries a genetic mutation that is responsible for heFH. 
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
About Regeneron Pharmaceuticals, Inc.Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products in the United States, ARCALYST ® (rilonacept) Injection for Subcutaneous Use and EYLEA ® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products. A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP ® (aflibercept) Concentrate for Intravenous Infusion. Phase 3 studies are in progress with EYLEA ® in a third indication, and with product candidate sarilumab. Earlier-stage clinical programs are underway with nine additional monoclonal antibodies. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at http://www.regeneron.com. Sanofi Forward-Looking Statements